Iron Deficiency Anemia Treatment with Ferric Derisomaltose

Dosing Guidelines

The European Society of Cardiology recommends that the dose of ferric derisomaltose be based on body weight and hemoglobin level, with a dose of 1000 mg for patients weighing less than 70 kg and hemoglobin levels between 10-12 g/dL for women or 10-13 g/dL for men 1, 2, 3
For patients weighing 70 kg or more with hemoglobin levels between 10-12 g/dL for women or 10-13 g/dL for men, a dose of 1500 mg is recommended, while those with hemoglobin levels between 7-10 g/dL may require a dose of 2000 mg 3

The American Heart Association suggests that ferric derisomaltose should be administered as an intravenous infusion over 15-30 minutes, with no test dose required before administration, unlike with iron dextran preparations 1
Resuscitation facilities should be available during administration due to the small risk of hypersensitivity reactions, as recommended by the European Journal of Heart Failure 1, 4

The American College of Gastroenterology recommends intravenous iron therapy with ferric derisomaltose for patients with intolerance to oral iron therapy, inadequate response to oral iron therapy, need for rapid iron repletion, hemoglobin below 10 g/dL, active inflammatory bowel disease, or chronic kidney disease with iron deficiency anemia 1, 2, 3, 4, 5

The European Journal of Heart Failure recommends monitoring hemoglobin concentration and red cell indices at 3-month intervals for the first year after iron repletion, then after another year 4, 6
Iron status should be re-evaluated 3 months after treatment, as ferritin levels are markedly increased immediately following IV iron administration, according to the European Journal of Heart Failure 1

The European Society of Cardiology states that contraindications to ferric derisomaltose include hypersensitivity to the active substance or any excipients, known serious hypersensitivity to other parenteral iron products, anemia not attributed to iron deficiency, or evidence of iron overload or disturbances in iron utilization 1

Monofer (ferric derisomaltose) should be administered intravenously when oral iron is contraindicated, ineffective, or not tolerated for treating iron deficiency anemia, as recommended by the European guidelines 7, 8
Intravenous ferric derisomaltose is indicated in patients with intolerance to oral iron therapy, as stated by the Clinical Gastroenterology and Hepatology guidelines 8
Intravenous ferric derisomaltose is indicated in patients with active inflammatory bowel disease with compromised absorption, according to the Clinical Gastroenterology and Hepatology guidelines 9
Intravenous ferric derisomaltose is indicated in patients who have undergone post-bariatric surgery with disrupted duodenal iron absorption, as recommended by the Clinical Gastroenterology and Hepatology guidelines 8

Avoid administering ferric derisomaltose on the same day as anthracyclines in cancer patients due to theoretical risk of potentiating cardiotoxicity, as warned by the American Journal of Hematology 10
Monitor hemoglobin concentration and red cell indices at 3-month intervals for the first year after iron repletion, and re-evaluate iron status 3 months after treatment, as recommended by the Gut guidelines 7

The patient has documented iron deficiency confirmed by bone marrow examination showing iron 3+ of 6, which is considered the most sensitive testing for iron status 11
The patient's transferrin saturation is 18%, which falls below the normal range of 20-50%, meeting criteria for iron deficiency anemia 11
While the ferritin level is within normal range, bone marrow examination is more sensitive and definitive for diagnosing iron deficiency 11

Ferric derisomaltose allows for complete iron repletion in a single infusion, improving patient convenience and potentially adherence 12
Iron derisomaltose has a lower risk of hypophosphatemia compared to ferric carboxymaltose, making it a safer option for many patients 12